Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis

This publication has 65 references indexed in Scilit:

• S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits
  Atherosclerosis, 2005
• Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
  Circulation, 2005
• Inflammation, Atherosclerosis, and Coronary Artery Disease
  New England Journal of Medicine, 2005
• Characterization of the oxidation products of BO-653 formed during peroxyl radical-mediated oxidation of human plasma
  Free Radical Biology & Medicine, 2005
• 8‐isoprostane increases scavenger receptor A and matrix metalloproteinase activity in THP‐1 macrophages, resulting in long‐lived foam cells
  European Journal of Clinical Investigation, 2004
• COX-2 and beyond: approaches to prostaglandin inhibition in human disease
  Nature Reviews Drug Discovery, 2003
• Lipid Peroxidation and the Aging Process
  Science of Aging Knowledge Environment, 2002
• No Effect of Cyclooxygenase Inhibition on Plaque Size in Atherosclerosis-prone Mice
  Scandinavian Cardiovascular Journal, 2002
• The Thromboxane Receptor Antagonist S18886 but Not Aspirin Inhibits Atherogenesis in Apo E–Deficient Mice
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2000
• Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
  New England Journal of Medicine, 1984